Sun Kerry T, Mok Sue-Ann
Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada.
Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada.
Neurotherapeutics. 2025 Apr;22(3):e00512. doi: 10.1016/j.neurot.2024.e00512. Epub 2025 Jan 3.
Amyloidogenic protein aggregation is a pathological hallmark of Alzheimer's Disease (AD). As such, this critical feature of the disease has been instrumental in guiding research on the mechanistic basis of disease, diagnostic biomarkers and preventative and therapeutic treatments. Here we review identified molecular triggers and modulators of aggregation for two of the proteins associated with AD: amyloid beta and tau. We aim to provide an overview of how specific molecular factors can impact aggregation kinetics and aggregate structure to promote disease. Looking toward the future, we highlight some research areas of focus that would accelerate efforts to effectively target protein aggregation in AD.
淀粉样蛋白生成性蛋白质聚集是阿尔茨海默病（AD）的一个病理标志。因此，该疾病的这一关键特征在指导关于疾病机制基础、诊断生物标志物以及预防和治疗方法的研究中发挥了重要作用。在此，我们综述了已确定的与AD相关的两种蛋白质——淀粉样β蛋白和tau蛋白——聚集的分子触发因素和调节因子。我们旨在概述特定分子因素如何影响聚集动力学和聚集体结构以促进疾病发展。展望未来，我们重点介绍了一些研究领域，这些领域将加速有效靶向AD中蛋白质聚集的研究工作。
